GSK Advances Liver Disease Pipeline With New Efimosfermin Alfa Trial

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

Study Overview

GlaxoSmithKline (GSK) is launching a Phase 1 trial titled “A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease.” The study will test how the experimental drug efimosfermin alfa behaves in the body and how safe it is in adults with fatty liver disease and different levels of liver damage. For investors, this work matters because it supports GSK’s push into liver and metabolic disease, an area with growing medical need and rising commercial interest.

Intervention/Treatment

The study will test efimosfermin alfa, a drug given by injection under the skin. It is designed to treat liver damage tied to metabolic dysfunction and steatotic (fatty) liver disease, including more advanced stages with inflammation and scarring. All participants will receive a single dose so researchers can see how the drug moves through the body and how well it is tolerated in people whose liver function is already impaired.

Study Design

This is an interventional study, meaning participants are actively treated with the drug. It is non-randomized and uses a sequential design: groups with different levels of liver damage are treated in sequence rather than all at once. The trial is open-label, so both doctors and participants know they are receiving efimosfermin alfa. The main goal is treatment-focused: to understand if the drug can be used safely and appropriately dosed in patients with moderate to severe liver impairment.

Study Timeline

The study was first submitted on 14 January 2026, showing it is a new addition to GSK’s pipeline. The latest update was filed on 27 January 2026, signaling active planning and regulatory engagement. Primary completion and overall completion dates are not yet listed, which is typical for an early-stage trial that has not started recruiting and suggests data readouts are still some distance away.

Market Implications

This clinical update underscores GSK’s commitment to building a presence in metabolic and liver disease, a space drawing strong attention after high-profile advances in obesity and NASH/MASH therapies. While a small Phase 1 study will not move earnings, it can support a pipeline narrative that investors value, especially if GSK can show that efimosfermin alfa is safe in higher-risk liver patients. Positive progress could gradually improve sentiment around GSK’s long-term growth story, positioning it against peers investing in fatty liver disease and metabolic drugs. However, the “not yet recruiting” status means there is no new efficacy data, so near-term stock impact is likely limited and driven more by perception of pipeline breadth than by fundamentals. The study remains ongoing in setup, with further details available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.